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-Galactosidases (EC 3.2.1.22) are retaining glycosidases that
cleave terminal -linked galactose residues from glycoconju-
gate substrates. -Galactosidases take part in the turnover of
cell wall–associated galactomannans in plants and in the lyso-
somal degradation of glycosphingolipids in animals. Deficiency
of human -galactosidase A (-Gal A) causes Fabry disease
(FD), a heritable, X-linked lysosomal storage disorder, charac-
terized by accumulation of globotriaosylceramide (Gb3) and
globotriaosylsphingosine (lyso-Gb3). Current management of
FD involves enzyme-replacement therapy (ERT). An activity-
based probe (ABP) covalently labeling the catalytic nucleophile
of -Gal A has been previously designed to study -galactosi-
dases for use in FD therapy. Here, we report that this ABP labels
proteins in Nicotiana benthamiana leaf extracts, enabling the
identification and biochemical characterization of an N. ben-
thamiana -galactosidase we name here A1.1 (gene accession
ID GJZM-1660). The transiently overexpressed and purified
enzyme was a monomer lacking N-glycans and was active
toward 4-methylumbelliferyl--D-galactopyranoside substrate
(Km 0.17 mM) over a broad pH range. A1.1 structural analysis
by X-ray crystallography revealed marked similarities with
human -Gal A, even including A1.1’s ability to hydrolyze Gb3
and lyso-Gb3,which are not endogenous in plants.Of note, A1.1
uptake into FD fibroblasts reduced the elevated lyso-Gb3 levels
in these cells, consistent with A1.1 delivery to lysosomes as
revealed by confocal microscopy. The ease of production and
the features of A1.1, such as stability over a broad pH range,
combined with its capacity to degrade glycosphingolipid sub-
strates, warrant further examination of its value as a potential
therapeutic agent for ERT-based FD management.
-Galactosidases (EC 3.2.1.22) occur widely in plants, ani-
mals, and microorganisms. Based on primary and secondary
structures, they are classified into the three glycoside hydrolase
families 4, 27, and 36. Family 27 contains mainly eukaryotic
-galactosidases removing terminal-galactosylmoieties from
glycoconjugates (1–3). Plant-galactosidases are so far known to
participate in the catabolism of galactosyl-sucrose oligosaccha-
rides, raffinose family of oligosaccharides, and cell wall galacto-
mannans primarily during germination of seeds (1, 4–7). In man,
a single -galactosidase occurs in lysosomes, -galactosidase A
(-Gal A),2 and is primarily responsible for themetabolism of gly-
cosphingolipids (8, 9).
A well-established classification of the plant enzymes is
based on their pH optimum for enzymatic activity: acidic ones
with broad pH optima from 4.5 to 6.5, and alkaline ones with
pH optimum between 7.0 and 7.5 (1, 10). These two classes of
plant -galactosidases might differ in localization. The acidic
-galactosidasesmost likely locate inside the vacuoles and apo-
plast, whereas alkaline -galactosidases act in the cytoplasm
with a neutral pH, where they might catalyze removal of termi-
nal galactose residues of substrates (1, 10). One of the first plant
-galactosidases to be cloned and biochemically characterized
was an enzyme from coffee beans (11). It occurs as two different
isoforms with molecular masses of 28 and 36.5 kDa showing
slightly different pH optima (pH 5.3 and 6.3) and isoelectric
points (12, 13). Similar heterogeneity of -galactosidases exists
in other plant species, for example in rice (6). Interestingly, the
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acidic plant -galactosidases are most homologous to the
human enzyme (1). For example, rice -galactosidase shows
37% homology in amino acid sequence to human -Gal A (5).
The human -Gal A enzyme is able to cleave -1,4-linked
galactosyl moieties from glycosphingolipids such as globotri-
aosylceramide (Gb3; ceramide trihexoside) and galabiosylcer-
amide and from blood groups B, B1, and P1 antigens. The
hydrolase is encoded by the GLA gene (gene ID, 2717) at locus
Xq22 (14). Itsmature form lacking the signal sequence contains
398 amino acids with three N-glycans, naturally forming
homodimers (14–17).Mannose 6-phosphatemoieties (Man-6-P)
on the threeN-linked glycans of-Gal Amediate the transport of
newly formed enzyme to lysosomes by Man-6-P receptors
(MPRs). Alternative sorting via the mannose receptor pathway
was suggested by Sakuraba et al. (18) and Shen et al. (19).
Dysfunction or absence of -Gal A leads to Fabry disease
(FD), anX-linked lysosomal disorder characterized by accumu-
lation of glycosphingolipids with terminal galactosyl moieties
in tissues and body fluids of FD patients (9, 20). The classic
manifestation of FD in males involves development of acro-
parasthesias, corneal clouding, and neuronopathic pain fol-
lowed by later-onset renal and cardiac disease and strokes.
Female carriersmay develop an attenuated disease. In so-called
atypical manifestations of FD, associated with missense muta-
tions in -Gal A, pathology is to a single organ like heart or
kidney and only develops late in life (9).
Enzyme-replacement therapy (ERT) with an MPR-targeted
recombinant enzyme is used to treat FD (15, 21). Two thera-
peutic enzymes (agalsidase , Replagal, and agalsidase ,
Fabrazyme) produced in mammalian cells are in use, and a
plant-produced enzyme is being developed (18, 22). The effi-
cacy of present ERT interventions is considered to be poor (23).
Unfortunately, most male FD patients lack the -Gal A protein
and consequently develop neutralizing antibodies against the
therapeutic recombinant enzymes that might contribute to the
noted poor responses to current treatments (24). Indeed, it was
recently reported that compared with agalsidase inhibition-nega-
tivemen, agalsidase inhibition-positive men showed greater left
ventricular mass and substantially lower renal function (25).
Additionally, these patients presented more often with symp-
toms such as diarrhea, fatigue, and neuropathic pain. Despite
the lack of residual -Gal A, even in classic male FD patients,
Gb3 accumulation is leveling with age. In Fabry patients, accu-
mulating Gb3 is alternatively metabolized in lysosomes by acid
ceramidase to globotriaosylsphingosine (lyso-Gb3) (26). In
plasma of male FD patients and mice, lyso-Gb3 is several hun-
dredfold elevated, an abnormality that can be exploited for
diagnosis andmonitoring of disease progression and therapeu-
tic correction (27–30). Excessive lyso-Gb3 is toxic for nocicep-
tive neurons and podocytes, which might explain the develop-
ment of neuronopathic pain and renal failure in FDpatients (31,
32). Again, the formation of neutralizing antibodies in male FD
patients receiving ERT is reported to impair reduction in
plasma lyso-Gb3 (24).
Recently, novel chemical tools have been developed to study
different retaining glycosidases, including -galactosidases (33,
34). These activity-based probes (ABPs) are mechanism-based
irreversible inhibitors functionalized with a bio-orthogonal tag
such as a fluorophore or biotin. The first of these, ABPs, was
developed for retaining -glucosidases such as the human lys-
osomal glucocerebrosidase (GBA). The natural glucosyl-con-
figured suicide inhibitor cyclophellitol covalently binds the cat-
alytic nucleophile residue, Glu-340, in the enzymatic pocket of
GBA (35). Equipped with a fluorescent reporter, the C-6 func-
tionalized cyclophellitol permits specific and sensitive visual-
ization of active enzyme molecules. Their amphiphilic nature
renders the fluorescent ABPsmembrane-permeable and allows
in situdetection of active glucocerebrosidase in cells and organ-
isms. Subsequently, cyclophellitol aziridine–type probes were
developed to label, again in a mechanism-based manner, a
broad range of -glucosidases (36, 37). Next, the approach was
extended to other retaining glycosidases by variation of the
cyclophellitol configuration, yielding ABPs for -galactosi-
dases, -galactosidases, -fucosidases, and -glucuronidases
(38–41). Equipping the cyclophellitol scaffold with a biotin
allows streptavidin-mediated enrichment and subsequent
chemical proteomics experiments using LC-MS/MS. The suc-
cessful application of biotin-tagged ABPs in proteomics profil-
ing of -glucosidases from different plant species was demon-
strated (42). A potent fluorescent -galactosyl–configured
cyclophellitol aziridine ABP was developed and shown to label
human -Gal A as well as -Gal B, the homologous N-acetyl
galactosaminidase arisen by a gene duplication (39).
In this study, we used fluorescent -galactosyl-configured
cyclophellitol-aziridine ABPs and synthesized a biotinylated
cyclophellitol-aziridine ABP to search for -galactosidases in
Nicotiana benthamiana. With these tools, we were able to
identify an abundant apoplast -galactosidase.We successfully
cloned the gene and transiently overexpressed the protein,
which we named A1.1, in N. benthamiana leaves. The recom-
binant enzyme was purified, crystallized, and biochemically
characterized.We here report on the outcome of the investiga-
tion, including a comparison of the plant -galactosidase with
the human enzyme, which is deficient in FD patients.
Results
Screening for-galactosidases in N. benthamiana leaf
extracts and apoplast fractions
N. benthamiana leaf extracts and apoplast samples thereof
were prepared and examined for -galactosidase activity using
4-methylumbelliferyl–-D-galactose (4MU–-Gal) as sub-
strate. Enzyme activity, with a broad pH optimum of 5.0–6.7,
was detected in both samples (Fig. 1A). Next, we incubated the
leaf and apoplast samples with Cy5-functionalized TB474 ABP
at different pH values. In the case of the leaf extract, Cy5-ABP–
labeled proteins with apparent molecular mass of 39 and 45
kDa were detected (Fig. 1B). The apoplast fraction contained
mainly the 39-kDa labeled protein (Fig. 1B). To assess
whether the plant -galactosidases of interest are glycosylated,
their binding to concanavalin A (ConA)-Sepharose beads was
examined (Fig. 1,C andD). After incubation of sampleswith the
lectin beads, ABP labeling and 4MU–-Gal activities were per-
formed. The39-kDa protein did not bind to the lectin beads,
in contrast to the 45 kDa protein (Fig. 1C). Approximately
50–55% of the 45-kDa protein is bound to the lectin beads, as
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judged by quantification of the band intensity of Fig. 1C. This
band corresponds to 5–10% of the total 4-MU–-Gal activity,
suggesting that the 45-Da protein is not as active as the 39 kDa
protein. More than 80% of the total 39-kDa labeled protein in
both lysate and apoplast fractions was found in the unbound
material. Likewise,more than70%of the total activity of both frac-
tions was not precipitated by ConA beads (Fig. 1D). The 39-kDa
protein is highly present in the apoplast fraction. Thus, a discrete
-galactosidase, possibly lacking high-mannose N-glycans, is
secreted to the apoplast space ofN. benthamiana leaves.
Figure 1. Screening for -galactosidases in N. benthamiana. Plant leaf lysates and apoplast samples were tested on their -galactosidase activity via
4MU–Gal assays and ABP in vitro labeling, following in-gel detection of the labeled proteins. A, 4MU–-Gal activities present in plant leaf lysates and apoplast
sampleswere first examinedatdifferentpHvaluesof 3–8. (n2, error bars indicatemeanS.D.)B,45gofplant leaf lysate and12gof apoplast samplewere
incubated with 0.25 M TB474 for 30 min at pH 4–7 at room temperature. Labeled proteins were detected via in-gel fluorescent scanning (ABP), and the gels
were stained with Coomassie Brilliant Blue (CBB) to show equal total protein loading. C, plant leaf lysates and apoplast samples were incubated with ConA-
Sepharosebeads for 2 h at 4 °C. After incubation, the sampleswere centrifuged, anddifferent fractionswere tested for-galactosidase activity via ABP labeling
and (D, left panel) 4MU–-Gal assays. (n 2, error bars indicate mean S.D.) In addition, D, right panel, quantification of the band intensity of C is presented.
Samples tested: starting material sample prior to ConA-Sepharose bead incubation, containing all proteins. Unbound supernatant after incubation with
the beads and centrifugation. This sample contains all material not bound to the beads.Washwash of the beads. Beads pellet after incubation with the
beads and centrifugation, containing the proteins attached to the ConA-Sepharose beads.
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Identification of potential N. benthamiana-galactosidases
Newly designed biotinylatedABPME741 (Fig. 2A) was found
to completely compete labeling of plant -galactosidase in the
apoplast fraction and leaf extracts by the Cy5-TB474 ABP (Fig.
2B). Conversely, labeling of plant -galactosidase by biotiny-
latedME741 (visualized byWestern blotting with streptavidin-
HRP) is blocked by prior incubation with TB474 ABP. Thus,
both probes recognize the same -galactosidases. Next, we
conducted large-scale pull downs of the -galactosidases pres-
ent in leaf and apoplast samples using biotinylated ME741.
After the pulldown, the target proteins were bound to strepta-
vidin beads following bead tryptic digestion. Tryptic peptides
were analyzed by nanoscaleLCcoupled to tandemMS(nano-LC-
MS/MS) (43). Peak listswere then searched against the Swiss-Prot
(version June, 2017) database, and the identified peptides were
manually curated. In this manner, peptides from known, well-an-
notated plant -galactosidases, similar in sequence to potential
N. benthamiana -galactosidases, were identified (Table S1).
The identified peptides belonged to Coffea arabica -galacto-
sidase (protein accession code Q42656) and Arabidopsis thali-
ana -galactosidase 1 and 2 (protein accession codes Q9FT97
and Q8RX86, respectively). Next, we conducted alignment
analysis of the cDNA sequence encoding for C. arabica -ga-
lactosidase, as it is a well-characterized protein, known not to
beN-glycosylated, toward the cDNA sequence ofN. benthami-
ana (Sol Genomics Network). Based on the alignment, we
designed specific primers to amplify the gene encoding for that
most similar to Coffee,N. benthamiana -galactosidase, which
Figure 2. Pulldown of plant -galactosidases usingME741 and their identification by proteomics. A, i, -galactosidase-configured aziridine scaffold; ii,
Cy5 ABP, TB474; iii, biotin ABP, ME741. B, to prove that the same -galactosidases are recognized by both ABPs, ME741 and TB474, competition experiments
were performed. -Galactosidases present in apoplast and plant leaf lysates were incubated with 0.25 M ME741, at pH 5.5, for 30 min at room temperature,
with or without subsequent incubation with 0.25M TB474, under the same conditions. Similarly, the samples were incubated first with TB474 and then with
ME741. The labeled proteins were detected via in-gel fluorescent scanning and Western blot analysis using streptavidin-HRP (dilution 1:4000). The blot was
then stained with CBB to show equal protein loading. The black arrow indicates the 45-kDa band; the open arrow indicates the 29-kDa protein, and the gray
arrow indicates unspecific biotinylated plant proteins.
Plant-galactosidase shows great similarity to human enzyme
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we named A1.1. An additional peptide search was then con-
ducted, after the insertion to the Swiss-Prot database of this
new potential N. benthamiana enzyme, and the results were
even more prominent (Table S2). We could identify more pep-
tides, with better scores and higher protein coverage, indicating
that this is the protein we were looking for and not the homo-
logues from the other organisms.
N. benthamiana A1.1 purification and characterization
To verify that A1.1 is truly an active-galactosidase, we tran-
siently overexpressed the enzyme via the Agrobacterium tume-
faciens infiltration of N. benthamiana leaves. The p19 RNAi
silencing inhibitor was used to ensure optimumprotein expres-
sion levels (44). Leaves were harvested at different days post-
infiltration (dpi), and A1.1 expression in the total leaf as well as
in apoplast fluid was detected by 4MU–-Gal activities, TB474
ABP labeling, and Coomassie Brilliant Blue staining of SDS-
polyacrylamide gels (Fig. 3,A andB). Optimal startingmaterials
for purification were apoplast fractions, collected at 4 dpi,
showing the highest 4MU–-Gal activity. The -galactosidase
activity per g of protein in apoplast fractions was 20–40-fold
higher in the case of leaves overexpressing A1.1, as compared
with those treated with empty vector or nontreated plant
leaves. A1.1 -galactosidase was purified to homogeneity in
three purification steps with high recovery (30%) (Table 1).
The presence of the enzyme in fractions was monitored by
enzymatic assay with 4MU–-Gal substrate. As the first puri-
fication step, we used ConA column chromatography, collect-
ing the unbound material (flow-through fraction). In this step,
other -galactosidases were removed by binding to the lectin
column. Next, cation-exchange chromatography was applied,
resulting in a further modest purification (recovery 40%).
Finally, the sample was subjected to gel-filtration chromatog-
raphy, revealing that A1.1 behaves asmonomer of about 30 kDa
(Fig. S1). The final preparation of A1.1 was apparently pure as
judged by SDS-PAGE analysis following silver staining of the
gel (see Fig. 3B for an overview of the entire purification).
A1.1 seems not to carry N-glycosyl groups as demonstrated
by the lack of effect of PNGase and EndoH on its molecular
weight (Fig. 3C). The molecular weight of A1.1, in contrast to
that of Fabrazyme, is not influenced after the endoglycanase
treatments (Fig. 3C). Consistently, following incubation of
A1.1 with PNGase A, no released N-glycans were detected by
MALDI-TOF MS analysis (Fig. S2).
Structural features of A1.1-galactosidase determined by
crystallography
Pure N. benthamiana A1.1 was crystallized. The protein
structure was determined at a resolution of 2.8 Å using the
molecular replacement method with the rice -Gal A (PDB
code 1UAS) as search model. The statistics data of the collec-
tion and refinement are listed in Table 2. The protein model is
a monomer, consisting of 363 amino acids (not including the
first 57 amino acid signal-peptide sequence) and being sepa-
rated into two domains. The N-terminal domain or catalytic
domain (1–278) contains a TIM (/)8-barrel, a commonmotif
among glycosidases (5), and the C-terminal domain (279–363)
contains eight -strands forming a “Greek key” motif (Fig. 4A).
The active site of the enzyme is found by prediction as the final
model obtained without a bound ligand, at the C-terminal end
of the catalytic domain. Similar to other glycoside hydrolases of
family 27, two aspartic acid residues (Asp-181 and Asp-236)
were observed to serve as the catalytic amino acids, one acting
as the nucleophile and the other as the acid/base, taking part in
the double displacement reaction mechanism of -galactosi-
dases (45). A1.1 is negatively charged at the site of its active site
and more neutral at the opposite site (Fig. 4B). The pI of the
enzyme is at around 5.32. Amino acid sequence alignment of
A1.1, human (protein accession code P06280), rice (protein
accession code Q9FXT4), and coffee (protein accession code
Q42656)-Gals reveals great secondary structure identity of all
enzymes (Fig. 4C). A1.1 shares 42% amino acid identity with the
human enzyme, showing overall highly conserved secondary
structures at the catalytic domain and not asmuch at the C-ter-
minal domain. No Asn-Xaa-(Ser/Thr/Cys) motifs are present
in amino acid sequences of A1.1, revealing that the protein is
most likelynotN-glycosylated. Incontrast, fourpotentialN-gly-
cosylation sites are present in human enzyme. A common
amino acid sequence pattern (CEW, at positions 212–214 in
Fig. 4C) occurs in all aligned galactosidases, as described previ-
ously by Motabar et al. (46).
The overall structure of A1.1 is very similar to that of human
(PDB code 3HG2) -Gal A, as visualized by the superimposed
models, consistent with their 42% sequence identity (Fig. 4D,
left panel). In addition, a closer look at the active site of both
enzymes shows great conservation of themajority of the amino
acids (Fig. 4D, right panel).
Catalytic features of A1.1
We first examined substrate specificity of pure A1.1 using
artificial 4-MU–glycoside substrates (Table 3). The enzyme
hydrolyzes with considerable affinity 4MU–-Gal substrate but
is inactive toward -D-glucopyranoside, -D-galactopyranoside,
-D-mannopyranoside, -L-fucopyranoside, N-acetyl--D-galac-
tosaminide, and N-acetyl--D-glucosaminide. The pH optimum
of A1.1 with 4MU–-Gal substrate is broad, ranging from pH 5.0
to 6.5 (Fig. 5A). The apparent Km with 4-MU–-Gal is 0.17 mM
and kcat 81 s1 (Fig. 5B). Comparable kinetic values are also
obtained with Fabrazyme, although its pH optimum toward
4MU–-Gal substrate is rather acidic at pH 4.5 (Fig. 5,A and B).
The structural resemblance of A1.1 with human -Gal A
prompted us to examine its activity toward glycosphingolipid
substrates. First, we tested the activity of A1.1 toward artificial
NBD-labeled Gb3. A1.1 was found to convert NBD-Gb3 toNBD-
lactosylceramide by removal of the terminal -linked galactose.
The activity ofA1.1 towardNBD-Gb3 is in several aspects compa-
rable with that of Fabrazyme (recombinant human -Gal A). The
pH optimum is similarly acidic at pH 4.5 (Fig. 5C). The affinity of
A1.1 for NBD-Gb3 is high with an apparent Km of 32 M, similar
again to that of Fabrazyme. However, the kcat value is 4-fold
lower than that of human -galactosidase (Fig. 5B).
Next, we tested natural glycosphingolipids as substrates.
A1.1 degrades natural C18-Gb3 by converting it to C18-LacCer
as measured by HPLC analysis (47). Its activity is again compa-
rable with that of human enzyme: 96.3% of C18-Gb3 is con-
verted to LacCer upon overnight incubation with 3 g of A1.1
Plant-galactosidase shows great similarity to human enzyme
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at pH 4.5 versus 98.3% conversion with the same amount of
Fabrazyme at the same condition. In addition, A1.1 hydrolases
best this lipid substrate (C18-Gb3) again at acidic conditions,
pH 4.6, the same as for the human enzyme (Fig. S3, A and B).
Finally, we determined by LC-MS/MS the ability of A1.1 to
degrade lyso-Gb3, the toxic base of Gb3, to lactosylsphingosine
(30). A1.1 degrades lyso-Gb3, showing a Km of 37 M, quite
comparable with that of Fabrazyme. Its kcat value, however, is
Figure 3. Overexpression andbiochemical characterization of the newly identifiedN. benthamiana-galactosidase, A1.1.A, transient overexpression
of A1.1 in N. benthamiana leaves via A. tumefaciens transformation assays. Infiltrated leaves and apoplast samples were harvested on different days post-
infiltration (dpi): 2, 4, and 6. The expression levels of the enzymewere first tested via 4MU–-Gal activities in lysates and apoplast fractions of different dpi. n
2. (A1.1 leaf overexpressing A1.1; E. empty vector; N. nontreated plant leaf.) B, next, the expression levels of active enzyme molecules were tested via
in-gel ABP labeling. CBB staining of the gels followed to ensure the presence of the overexpressed enzyme. (P.plant lysate;A. apoplast sample; E. empty
vector;N.nontreatedplant leaf.)C,purificationoverview. SDS-PAGEanalysis following silver stainingof fractionsobtainedduringdifferentpurification steps.
(St.M. startingmaterial;ConA fractionnotbound to concanavalinA column;D. sampleobtainedafter 48hofdialysis;C.E.pooled collectedeluate from
cation-exchange chromatography;G.F. final pooled fractionobtained after gel filtration.) 2gof total proteinwere loaded in each lane, except inG.F., where
1 g was loaded. D, SDS-PAGE analysis following Coomassie Brilliant Blue staining of 1 g of pure A1.1 and Fabrazyme after treatment with PNGase F and
EndoH (Cuntreatedpure enzyme; P enzyme treatedwith PNGase F; E enzyme treatedwith EndoH), shows that A1.1 is not likelyN-glycosylated,whereas
Fabrazyme is, due to the difference in molecular weight after treatment.
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2-fold lower than that of the human enzyme (Fig. 5B). The
noted activity of A1.1 toward glycosphingolipid substrates in
vitro resembles the earlier observed ability of rice -galactosid-
ase to hydrolyze Gb3 in vitro (48).
A1.1 reduces lyso-Gb3 in intact FD fibroblasts
At first the uptake of A1.1 from lysosomes of two different
FD patients’ fibroblasts was evaluated. Different amounts of
pre-labeled enzymewith TB474A1.1 were applied overnight to
the cells. After extensive washing (Fig. S4), the cells were lysed,
and the uptake of A1.1 was studied via SDS-PAGE analysis (Fig.
6A). The cells from both FD patients were able to uptake A1.1.
An increase in the uptake depending on the concentration of
the pre-labeled protein added to the culture media was
observed. To estimate the amount of the internalized enzyme,
1% of the input using 150 and 300 g/ml were loaded on gel,
together with 13–17% of the total lysates after treatment with
the prelabeled enzyme (Fig. 6B). The quantification of the gels
revealed that 0.3–0.6% of the 150 g/ml entered the cells, and
0.5–1% of the 300 g/ml (Fig. 6C).
In addition, the uptake of the enzyme was studied by confocal
microscopy. For this, A1.1 was again labeled with TB474 and
subsequently applied to the FD fibroblasts. After a 16-h
uptake, punctate fluorescence was observed in some cells,
which was reminiscent of a lysosomal pattern, possibly
through fluid-phase endocytosis. Immunofluorescent stain-
ing of the late endosomal/lysosomal marker LAMP-1 occa-
sionally showed co-localization with TB474-A1.1, indicating
lysosomal delivery of the enzyme (Fig. 6D).
To examine whether A1.1 is also able to degrade glycosphin-
golipid in vivo, we incubated the same cultured FD fibroblasts
Figure 4. Structural similarities of -galactosidases from different spe-
cies. A, stereo view of the ribbon model of A1.1 (PDB code 6F4C). Catalytic
domain contains a (/)8-barrel. C-terminal domain forms a Greek key.
-Strands are represented in green; -helices are represented in pink; and
loops are represented in light blue. B, electrostatic map of A1.1: red indicates
the charges; blue indicates the charges. C,multiple amino acid sequence
alignment of A1.1: human, rice, and coffee galactosidases. The sequence
alignment showing structural details of A1.1 was achieved using
ESPript3.0. -Helices are shown as coils labeled ; -strands are shown as
arrows labeled , and -turns are labeled TT. Identical residues are shown
on a red background; conserved residues are shown in red, and conserved
regions are shown as blue boxes. The catalytic residues are indicated with
an asterisk. D, right panel, stereo view of the superimposed models of A1.1
with the human -galactosidase. 348 residues were aligned, having a
root-mean-square deviation of 1.3358 Å of their C- atoms. The A1.1
model (PDB code 6F4C) is shown in green; the human -Gal model (PDB
code 3HG2) is shown in gray. The backbone of a modeled galactose mol-
ecule is shown in white, and its oxygen atoms are shown in red. Left panel,
a closer look at the amino acids around the active site of both enzymes,
presented as fat bonds.
Table 1
Overview of A1.1 purification
Purification steps
Protein
concentration Volume
Total
protein Total activity
Total specific
activity
Purification
fold
Yield recovery
activity
mg/ml ml mg mol/h/ml mol/h/mg %
Starting material 1.3 20 26 63,338 2436 1 100
ConA 0.44 45 20 50,171 2534 1 79
Dialysis 0.38 45 17 49,550 2905 1.2 78
Ion exchange 1.2 4.5 5.4 25,977 4810 2 41
Gel filtration 5 0.6 3 20,879 6959 2.9 33
Table 2
Data collection and refinement statistics (PBD code 6F4C)
Data collection
Space group P 41 21 2
Unit-cell parameters a, b, c, , ,  74.04Å, 74.04Å, 133.31Å
90.00, 90.00, 90.00
Resolution (Å) 25.00 2.80
24.77 2.80
% Data completeness (in resolution range) 98.4 (25.00–2.80)
99.9 (24.77–2.80)
	I (I)
 2.53 (at 2.80Å)
Refinement statistics
Refinement program REFMAC 5.8.0158
R, Rfree 0.216, 0.287
0.225, 0.282
Rfree test set 486 reflections (5.30%)
Fo, Fc correlation 0.88
Total no. of atoms 2861
Average B, all atoms (Å2) 4.0
Ramachandran plot (%)
Preferred regions 96
Allowed regions 3
Outliers 1
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with 300g/ml A1.1. After overnight incubation, the cells were
first washed and lysed, and the levels of both lyso-Gb3 and Gb3
were determined by LC-MS/MS. In addition, the 4MU–-GAL
cellular activity was measured. The elevated lyso-Gb3 and Gb3
in both FD fibroblasts were found to be significantly reduced by
the exposure to A1.1 (Fig. 7A). In addition, the 4MU–-Gal
cellular activitywas significantly increased after exposure to the
recombinant protein (Fig. 7B). Activities were alsomeasured at
washing steps 1 and 5 to ensure that no protein remained out-
side of the cells prior to lysis (Fig. S5).
Figure 4—continued
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Discussion
We earlier used N. benthamiana for expression of WT and
mutagenized human -galactosidase and -galactosaminidase
(49). The N. benthamiana plant is a convenient production
platform for recombinant proteins given the ease of cultivation
and transfectionwithA. tumefaciens (49). In our previous study
(49), we employed a cyclophellitol-type activity-based probe
(TB474) to visualize the recombinant human -galactosidases.
In the course of the experiments, we noted the presence of two
endogenous enzymes (39 and 45 kDa) labeled by TB474. We
focused attention to the 39-kDa enzyme (named A1.1) that is
present in relatively high concentrations in the apoplast. Using
biotin-containingABP (ME741) and streptavidin pulldown, the
identity of the 39 kDa protein in apoplast fluid was determined
by proteomics. The corresponding gene (accession ID: GJZM-
1660) was cloned from a N. benthamiana cDNA library and
transiently overexpressed inN. benthamiana leaves using infil-
trations with A. tumefaciens harboring the appropriate expres-
sion vectors. A high yield of A1.1 in the apoplast fluid was
obtained, comprising 11.5% of total soluble apoplastic protein.
Next, exploiting the lack of binding of A1.1 to ConA beads, the
protein was purified with 33% recovery to homogeneity by
sequential ConA chromatography, cation-exchange chroma-
tography, and gel filtration. The molecular mass of 39 kDa of
the purified enzyme is similar to that reported for rice and cof-
fee -galactosidases (3, 5, 6, 48).
We characterized A1.1 regarding structural features. The
mature form of the enzyme consists of 363 amino acids and has
a molecular mass of 39 kDa. The purified enzyme is an active
monomer, based on gel filtration behavior. This feature is com-
mon to rice -galactosidase, but the human enzyme occurs as a
homodimer (49). As predicted by the absence of appropriate
Asn-Xaa-(Ser/Thr/Cys) motifs, A1.1 is notN-glycosylated, and
endoglycanase digestion points to no N-linked glycans. Simi-
larly, rice and coffee -galactosidases lack N-glycans (5, 50).
Based on amino acid sequence alignments, the enzyme has 82%
identity with coffee -galactosidase, 68% identity with rice
-galactosidase, and 42% identity with human -galactosidase
A, also revealing great secondary structural conservation.
Crystals of pure A1.1 were obtained, and the structure was
resolved by X-ray diffraction at a resolution of 2.8 Å. The
enzyme contains a C-terminal domain with Greek key motif
and N-terminal domain with a (/)8-barrel, the common cat-
alytic domain among the hydrolases of family 27 (5). The active
site of retaining -galactosidases contains a catalytic nucleo-
phile and acid/base residue mediating double-displacement as
a catalytic mechanism (51, 52). In the active site of A1.1, other
amino acids appear involved in substrate recognition, such as
Trp-67, Asp-102, Tyr-144, and Lys-179. Two disulfide bonds
occur close to the catalytic pocket, Cys-72/104 and Cys-152/
Figure 4—continued
Table 3
Activity of A1.1 toward different 4MU substrates
4MU substrates Activity
nmol/h/g
-D-Glucopyranoside, pH 5.2 0
-D-Glucopyranoside, pH 5.8 8
-D-Glucopyranoside, pH 7 0
-D-Galactopyranoside, pH 4.6 905
-D-Galactopyranoside, pH 6 1645
-D-Galactopyranoside, pH 4.3 8
-D-Mannopyranoside, pH 4 3
-L-Fucopyranoside, pH 5.5 6
N-Acetyl--D-galactosaminide, pH 4.6 8
N-Acetyl--D-glucosaminide, pH 4.4 2
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183, as also present in human -galactosidase A (17, 51). Nota-
bly, the existence of a second ligand-binding site in human
-galactosidase A, centered on Tyr-329, was postulated by
Guce et al. (45). This putative site, speculated to bind -galac-
tose, is located between the two domains of the humanmonomer
enzyme, being exposed at the surface.However, inA1.1, insteadof
the Tyr-329, a Lys-330 is present, and the overall second binding-
site region is different from the human enzyme. The C-terminal
domain of A1.1 contains eight -strands forming a Greek key
motif. The C-terminal amino acid sequences of human and A1.1
-galactosidases are different. Coffee -galactosidase, however,
containsaC-terminaldomain that is similar toA1.1and is thought
to essentially contribute to the overall structure of the enzyme, as
its deletion results in loss of enzymatic activity (3).
A1.1 shows strong specificity regarding the substrate sugar.
It hydrolyzes 4MU–-galactopyranoside liberating fluorescent
methylumbelliferone, but it does not correspond to -D-gluco-
pyranoside,-D-galactopyranoside,-D-mannopyranoside,-L-
fucopyranoside, N-acetyl--D-galactosaminide, or N-acetyl--
D-glucosaminide. The broad pH optimum of A1.1, pH 5.0–6.5,
is also reported for coffee and rice enzymes (12, 48). The activity
of A1.1 toward 4MU–-galactopyranoside (Km of 0.17 mM) is
quite comparable with that of human -galactosidase A (Km of
2.4mM). For the rice enzyme, a high affinity toward pNP–-Gal
substrate was earlier reported by Chien et al. (48) (Km of 0.47
mM). For coffee-galactosidase, a pH optimumof 6.5 with aKm
of 0.29 mM toward 4MU–-Gal substrate was observed by
Maranville and Zhu (3).
-Galactosidases from rice and coffee have been shown to
remove terminal 1–3-linked galactose residues from type B
glycolipid antigens on red blood cells, converting them to type
O structures (48, 53). The ability of A1.1 to hydrolyze terminal
-galactoses from artificial and natural glycosphingolipid sub-
strates was therefore studied. A1.1 was found to be well able to
hydrolyze NBD-Gb3, C18-Gb3, and lyso-Gb3 in vitro. Of note,
the presence of Gb3 in N. benthamiana leaves has not been
reported. We could not detect Gb3 with a regular sphingolipid
base (data not shown). A similar observation was earlier made for
rice -galactosidase; Gb3 was shown to be converted to LacCer,
but kinetic parameters were not determined (48). We observed a
considerableaffinityofpureA1.1 for lipidsas substrates (Kmvalues
of 32 M for NBD-Gb3 and 38 M for lyso-Gb3), almost equal to
those observed for human -galactosidase A.
Presently, two different recombinant human-galactosidase
A preparations are used to treat FD, an X-linked disorder with
lysosomal Gb3 accumulation in various cell types and affecting
heart and kidney (54). The therapeutic enzymes use Man-6-P
containing N-linked glycans that are aimed to correct the lyso-
somal enzyme deficiency in all cell types following uptake and
delivery to lysosomes by the ubiquitous MPR at the surface
of cells (54). Exposure of cultured fibroblasts to recombinant
human -galactosidase A (Fabrazyme) results in a reduction of
excessive Gb3 and is deacylated metabolite lyso-Gb3 (54). We
investigated whether recombinant A1.1 also manages to
degrade the toxic lyso-Gb3 accumulating in cells of FDpatients.
Indeed, an overnight incubation of patient fibroblasts with 300
g/ml A1.1 resulted in significant reduction of both lyso-Gb3
and Gb3 accumulating glycosphingolipids, reaching levels
found in normal fibroblasts (4 pmol/mg and 15 nmol/mg
for lyso-Gb3 and Gb3, respectively). It should be kept in mind
that because A1.1 lacks glycans, no lectin-mediated uptake of
the enzyme by cells occurs, in contrast to that ofMan-6-P–rich
Fabrazyme. The ability of the latter enzyme to correct lyso-Gb3
in cultured fibroblasts is therefore far superior than that of
A1.1. A same reduction in cellular lyso-Gb3 of FD fibroblasts
was obtained, reaching levels found in normal fibroblasts, with
60-fold less Fabrazyme than A1.1 (Fig. S6).
Figure 5. Activity ofN. benthamianaA1.1 and Fabrazyme toward 4MU--GAL and humanglycosphingolipids. A, 4MU–-Gal activities of pure A1.1 and
Fabrazyme at different pH values (3.8–8). B, Michaelis-Menten kinetic values of both enzymes toward 4MU–-Gal, NBD-Gb3, and lyso-Gb3 substrates. Data
represent mean values, n 2. C, degradation of 5M NBD-Gb3 to NBD-LacCer by 50 ng of A1.1 or Fabrazyme at varying pH values (4.5–7.5). Quantification of
HPTLC plates were conducted more than once, showing one gel quantification.
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Unfortunately, the present enzyme replacement therapies
meet limited clinical success. Although storage lipid is cleared
from endothelial cells, complications in heart and kidney may
nevertheless develop in FD patients, possibly due to the use of
insufficient therapeutic enzyme to penetrate these organs.High
costs of the present -galactosidase A preparations hamper the
use of significantly higher doses. The elevated circulating lyso-
Gb3, considered to be toxic for podocytes and nociceptive neu-
rons, is not completely corrected by present ERT (30, 31).
Finally, a complicating factor with the present ERT of FD
proves to be the antigenicity of recombinant human -galacto-
sidase A in the majority of male FD patients that lack any
endogenous enzyme (25). In these individuals, neutralizing
antibodies against therapeutic enzyme develop quickly, result-
Figure 6. Internalization of TB474-labeled A1.1 from Fabry fibroblasts. A, Fabry fibroblasts from two different patients were grown in 12-well plates. The
cells were incubated with different amounts pre-labeled with TB474, A1.1 (0, 5, 10, 70, 150, and 300g per 1ml of culturemedia). Lysis of the cells took place,
and samples were measured for Cy5 signal, through SDS-PAGE. Left top panel, results were obtained when using patient 1 cell line, SDS-polyacrylamide gel
image, following fluorescent scanning and quantification of signal, left bottom panel. Right panel, results obtained from patient 2 cell line. The gels were
conducted more than once. The uptake is gradually increased while increasing the amount of pre-labeled protein in both cell lines. 10 g of total fibroblast
proteinwas added in eachwell. Coomassie staining of the cells took place to showequal loading.ABP activity-based probe signal;CBBCoomassie Brilliant
Blue signal; P1 patient 1; P2 patient 2. B, estimation of the % of the internalization of pre-labeled A1.1 (150 and 300 g per ml of culture media) from the
same FD fibroblasts. Loaded on gel, 1% of the pre-labeled A1.1 input, together with 10 g of total fibroblast protein, accounted for 13–17% of the total cell
lysate. C, quantification of signal obtained in B. The uptake of 150 g of A1.1 accounts to 0.3–0.5% of the total input and 0.5–1% when using 300 g. ABP
activity-based probe signal; P1  patient 1; P2  patient 2. D, overnight uptake of A1.1, pre-labeled with TB474, by FD fibroblasts monitored by confocal
microscopy. Cells were grown overnight on glass coverslips and incubated with 150 g of pre-labeled A1.1 per ml of culture medium (here shown cells from
patient 1).Panel in red, visualizationof the internalized TB474-labeledA1.1.Panel in green, lysosomal labelingusing anti-LAMP-1 antibody.Panel in blue, cellular
nuclei stained with DAPI. D, overlay image. The white arrowheads indicate examples of co-localization of internalized TB474-labeled A1.1 with the late
endosomal/lysosomal marker LAMP-1. Scale bar 25 m.
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ing in a relapse in the reduction of circulating toxic lyso-Gb3
(24). The clinical outcome of ERT in antibody-positive FD
patients is reported to be poorer (24). In view of all this, the use
of a plant -galactosidase to treat male FD patients deserves
consideration. First, plant-galactosidase could be produced in
N. benthamiana or other plant production platforms at consid-
erable lower costs than the present human recombinant
enzymes, allowing use of higher doses. Second, A1.1 is able to
degrade toxic lyso-Gb3. The enzyme can in principle be further
engineered to increase stability and desired enzymatic activity.
The lack of N-glycans on a plant-derived -galactosidase might
even be beneficial, preventing a lectin receptor-mediated sink in
the endothelium and liver as observed with present therapeutic
human glycoprotein enzymes. Finally, we observed that N. ben-
thamiana A1.1 does not cross-react with neutralizing antibodies
directed against human -galactosidase A that are present in
serum of male FD patients treated with therapeutic enzyme (Fig.
S7). Antigenicity of a plant protein might be a concern, but it
shouldbekept inmindthat this alsoexistswith thehumanenzyme
preparations inmostmale FDpatients. The considerable progress
made in induction of tolerance against foreign proteins may be
exploited (55). It is presently unclear how antigenic a plant -ga-
lactosidase will be: the absence of glycans might reduce C-type
lectin receptor-mediated presentation by dendritic cells.
In conclusion, further research on the optimization of plant
-galactosidases such as A1.1 to reduce toxic lyso-Gb3 in FD
should be considered to meet the need for an affordable treat-
ment of this devastating disorder.
Experimental procedures
Chemicals
All chemicals were obtained from Sigma (Germany) if not
indicated otherwise. Fluorescent NBD-lipids and pure lipids
were purchased fromAvanti Polar Lipids (Alabaster, AL). Anti-
bodies purchased from Abcam (Cambridge, MA).
Plants
N. benthamiana plants were grown at 21 °C and 60–70%
humidity intheUnifarmgreenhousesofWageningenUniversity(56).
Patientmaterials
Fibroblast cell lines from classical FD individuals were
obtained from the Lysosomal Outpatient Clinic of the Aca-
demic Medical Center in Amsterdam (AMC). The cells were
cultured in Dulbecco’s modified Eagle’s medium/Nutrient
Mixture F-12 (DMEM/F-12, Sigma)media, supplemented with
10% fetal calf serum and 1% penicillin/streptomycin, at 37 °C
with 5%CO2 in a humidified incubator. Plasma specimens from
FD individuals were obtained from the Lysosomal Outpatient
Clinic of theAcademicMedical Center in Amsterdam (see sup-
porting information). All patient materials were obtained after
approval of the Academic Medical Center’s review board and
abide by the Declaration of Helsinki principles.
ABPME741, synthesis
The -galactopyranose-configured cyclophellitol aziridine
grafted with Cy5 as fluorophore ABP (TB474) was synthesized
as described previously (49). The biotinylated-galactopyrano-
side cyclophellitol aziridine (ME741) was synthesized by cop-
per-catalyzed click chemistry of azido cyclophellitol aziridine
intermediate with biotin alkyne (Scheme S1). The -galactose-
configured azido cyclophellitol aziridine (39) (14.6 mg, 0.043
mmol) synthesized in 15 steps form D-xylose, and the desired
biotin-alkynes (18.5 mg, 0.047 mmol) were dissolved in N,N-
dimethylformamide (2 ml). CuSO4 (0.043 ml, 1 M in H2O) and
sodium ascorbate (0.043 ml, 1 M in H2O) were added, and the
reaction mixture was stirred at room temperature under argon
atmosphere for 18 h. Then the solution was diluted with
CH2Cl2, washed with H2O, dried over MgSO4, and concen-
trated under reduced pressure. The crudewas purified by semi-
preparative reversed-phaseHPLC (linear gradient: 15–24%B in
Figure 7. Correction of FD lipid abnormalities in Fabry fibroblasts via A1.1 treatment. A, lyso-Gb3 and Gb3 levels measured by LC-MS/MS in Fabry
fibroblasts from twodifferent patients, with orwithout overnight treatmentwith 300gof A1.1 perml of culturemedium. B, cellular 4MU–-Gal activity found
in the same lysates thatwere used for lipidmeasurements, before andafter treatmentwithA1.1. Data are represented asmean S.D.,n3.Asterisk(s) indicate
significant differences as measured by a standard t test: *, p 0.05; **, p 0.01; ***, p 0.001.
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A, 12 min, solutions used A, 50 mM NH4HCO3 in H2O, and B,
MeCN) and lyophilized to yield biotinylated ABP ME741 as a
white powder (8.0 mg, 11 mol, 26%). 1H NMR (600 MHz,
CD3OD) contained the following:  7.85 (d, J 3.7 Hz, 1H, CH);
4.90 (s, 1H,NH); 4.49 (dd, J 7.9, 4.9Hz, 1H, CH); 4.42 (d, J 2.3
Hz, 2H, CH2); 4.38 (td, J 7.1, 2.5 Hz, 2H, CH2); 4.30 (dd, J 7.9,
4.5 Hz, 1H, CH); 4.08 (dd, J 8.6, 3.9 Hz, 1H, CH); 3.85–3.87 (m,
1H, CH); 3.81–3.68 (m, 2H, CH2); 3.36 (dd, J  8.6, 1.7 Hz, 1H,
CH); 3.24–3.17 (m, 1H, CH); 3.16 (td, J 7.0, 2.5 Hz, 2H, CH2);
2.92 (dd, J 12.7, 5.0 Hz, 1H, 1/2CH2); 2.70 (d, J 12.7 Hz, 1H,
1/2CH2); 2.61 (d, J 6.1 Hz, 1H, CH); 1.91–1.86 (m, 4H, 2CH2);
1.75–1.56 (m, 4H, 2CH2); 1.51 (p, J7.2Hz, 2H,CH2); 1.43 (p, J
8.8, 8.2 Hz, 2H, CH2); 1.39–1.26 (m, 4H, 2CH2). 13C NMR (151
MHz, CD3OD) contained the following:  188.7, 176.0, 176.0,
166.1, 146.2, 146.2, 74.3, 74.2, 73.2, 73.1, 70.5, 69.5, 63.4, 62.8, 61.6,
57.0, 51.4, 51.3, 44.8, 43.3, 41.1, 40.2, 39.4, 37.1, 36.8, 36.8, 35.6,
31.3, 31.2, 30.4, 30.1, 30.0, 29.9, 29.8, 29.7, 29.5, 27.5, 27.4, 27.3,
27.2, 26.9, 26.5, 25.8ppm;HRMSwas calculated forC34H56N8O8S
[MH] 737.40201 and found was 737.40146.
N. benthamiana leaf extracts
Leaves of 5–6-week-old N. benthamiana plants were col-
lected, snap-frozen in liquidnitrogen, andhomogenizedby grind-
ing with a mortar and a pestle. To 1 g of leaf, 4 ml of ice-cold
extraction buffer (30mM citrate/phosphate buffer, pH 6, contain-
ing 2% w/v polyvinylpolypyrrolidone, 0.1% v/v Tween 20, 0.15 M
NaCl, and protease inhibitor by Roche Applied Science, EDTA-
free) was added, and the material was again homogenized. The
homogenates were centrifuged at 16,000 rcf, at 4 °C, for 10 min,
and the supernatant containing soluble proteins was collected.
Isolation of apoplast proteins
For the isolation of apoplast proteins,N. benthamiana leaves
were gently submerged in ice-cold extraction buffer (50 mM
PBS, pH 6, 0.1 M NaCl, and 0.1% v/v Tween 20) and exposed to
vacuum for 10 min. Then the vacuum was released very slowly
to ensure infiltration of the apoplast. The leaves were then col-
lected and carefully placed in 10-ml syringes plugged in 50-ml
tubes. The samples were centrifuged for 10min at 2000 rcf, and
apoplast fluid was collected (44).
Small-scale ABP labeling of-galactosidases in
N. benthamiana plant leaf extracts and apoplast fluid
10 l of N. benthamiana plant leaf extracts (4.5 mg of total
soluble protein/ml) and 20 l of apoplast sample (0.21 mg of
total soluble protein/ml) were incubated with 0.25 M fluores-
cent TB474 in 150 mM citrate/phosphate buffer at different pH
values, for 30 min at room temperature. Gel loading buffer
(with additional-mercaptoethanol)was added to samples, fol-
lowed by incubation for 5 min at 95 °C. The proteins in the
samples were separated by 10% polyacrylamide gels. Labeled
proteins were visualized by fluorescence scanning as described
earlier (34).
Analysis of N-glycosylation by concanavalin A lectin binding
ConcanavalinA-Sepharose 4B beads (ConAbeads) were first
washed three times in 0.1 M sodium acetate, 0.1 M NaCl, 1 mM
MgCl2, 1 mMCaCl2, 1 mMMnCl2, pH 6.0, washing buffer using
brief centrifugation at 2000 rcf for 2 min. Next, 150 l of beads
were mixed with 300 l of plant leaf extracts or 150 l of apo-
plast sample and incubated for 2 h at 4 °C while rotating. After
this incubation, the mixture was centrifuged at 16,000 rcf at
4 °C for 10 min. The supernatant was collected, and the beads
were washed three times with washing buffer. The samples
were stored for a short period at 4 °C until further use.
Competitive ABPP usingME741 ABP
The ability of biotinylated ME741 to label -galactosidases
was first established by performing competition experiments.
Homogenates were first labeledwithCy5 functionalized TB474
at 0.25 M for 30 min at room temperature, followed by labeling
the homogenatewith biotinylatedME741ABP at 0.25Mand the
other way around. Subsequently, SDS-PAGE and Western blot
analysis withHRP-streptavidinwas performed as described previ-
ously (41, 43).
In vitro biotin pulldown of bound targets, followed by on-bead
tryptic digestion and LC-MS/MS identification
Plant leaf extracts (4.5 mg of total soluble protein/ml) and
apoplast samples (0.21 mg of total soluble protein/ml (no. 1)
and 0.6 mg of total soluble protein/ml (no. 2)) were pre-incu-
bated or not with 5 M TB474 for 2 h at room temperature,
following overnight incubation with 5 M ME741, room tem-
perature at a final volume of 500 l. Then the reaction was
stopped by the addition of 120 l of 10% (w/v) SDS and subse-
quent incubation of the sample at 95 °C for 5 min. Preparation
of proteins for on-bead and tryptic digestion following LC-
MS/MS identification was performed exactly as described pre-
viously (43). Prior to LC-MS analysis, peptides were desalted by
Stagetips as described by Rappsilber et al. (57). EmporeTM C18
47-mm extraction discs were used to fabricate the StageTips.
Typically, two discs were placed on top of each other to make
StageTips with two layers of column material inserted in a yel-
low pipette tip.
MS acquisition
The SynaptG2Simass spectrometer (Waters) operatingwith
Masslynx for acquisition and ProteinLynx Global Server
(PLGS) for peptide identification was used for analysis. The
following settings in positive resolution mode were used:
source temperature of 80 °C; capillary voltage 3.0 kV; nano flow
gas of 0.25 bar; purge gas 250 liters/h; trap gas flow 2.0 ml/min;
cone gas 100 liters/h; sampling cone 25 V; source offset 25; lock
mass acquisition was done with a mixture of Leu-enkephalin
(556.2771) and Glu-fibrinogen (785.84265) and lockspray volt-
age 3.5 kV; and Glu-fibrinogen fragmentation was used as cali-
brant. An UDMSe data-independent acquisition method was
used for analysis. Briefly, the mass range is set from 50 to 2000
Da with a scan time of 0.6 s in positive resolution mode. The
collision energy is set to 4 V in the trap cell for low-energy MS
mode. For the elevated energy scan, the transfer cell collision
energy is ramped to higher collision energies, and data are
recorded. The lock mass is sampled every 30 s and used for
accurate determination of parent ions mass after peak picking.
Peak lists containing parent and daughter ions were compiled
in .mgf format and searched against the Swiss-Prot (version
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June 2017) database. The identified peptides were manually
curated.
Plant expression vector for overexpression of A1.1
The N. benthamiana -galactosidase A1.1 (gene accession
ID: GJZM-1660), was amplified from an N. benthamiana
cDNA library made by our laboratory using the InvitrogenTM
CloneMinerTM II cDNA library construction kit (Thermo
Fisher Scientific). The gene was amplified with its native signal
peptide, using Phusion High Fidelity PCR Master Mix (Bio-
Labs), with the following primers: sense, 5-CCCATGGGTTT-
GCCACCAATTTTAAAGCTGCTACTAT-3, and antisense,
5-GGGTACCTTATTTTTTAGGAGTCAGAACATACATC-
CTGCA-3. The gene was flanked between NcoI and Acc65I
restriction sites, and it was cloned into a pGEM-T Easy Vector
System (Promega). Confirmation of sequences was done by
sequencing (Macrogen, the Netherlands), and the complete
ORF of the gene was inserted into the pHYG plant expression
vector, as described previously (58). The construct was under
the control of cauliflower mosaic virus 35S constitutive pro-
moter, with duplicate enhancer and the nopaline synthase ter-
minator (49). The pHYGvectors harboring the geneswere used
for transformation ofA. tumefaciens strainMOG101, following
N. benthamiana plant leaf infiltrations.
A. tumefaciens transient transformation assay and plant
infiltrations
A. tumefaciens cultures were grown as described previously
(56, 58). The constructs were co-expressed with the tomato
bushy stunt virus silencing inhibitor p19 to ensure optimum
expression levels (44, 49). The inoculated bacterial cultures
were used for infiltration of 5–6-week-old N. benthamiana
plants, as described previously (56).
Isolation of apoplast overexpressing A1.1
The isolation of apoplast fluid was performed as described
previously (44), using as extraction buffer 30 mM citrate/phos-
phate, pH 6, 0.5 M NaCl, and 0.1% (v/v) Tween 20. The sample
was passed through a G-25 Sephadex column for desalting and
snap-frozen in liquid nitrogen. The sample was stored at
80 °C until further use.
Enzyme purification
Chromatography with 5 ml of concanavalin A-Sepharose
column (GEHealthcare) was used as a first step for purification.
The column was equilibrated with 40 ml of washing buffer (0.1
M sodium acetate, 0.1 M NaCl, 1 mM MgCl2, 1 mM CaCl2, 1 mM
MnCl2, pH 6.0). Then, 40 ml of apoplast fluid overexpressing
A1.1was applied to the column, 1:1, diluted inwashing buffer (1
ml/min loading conditions). The enzyme was present in the
(unbound) flow-through fractions, ensuring separation from
bound plant glycoproteins. About 40 ml of sample was col-
lected and tested for enzymatic activity. Next, the sample was
extensively dialyzed in 20 mM sodium acetate buffer, pH 5.5,
4 °C, for 2 days. Subsequently, the dialyzed fraction was sub-
jected to chromatography on two HiTrap SP HP columns, 1 ml
each, plugged on top of each other (GE Healthcare), and equil-
ibrated with 30 ml of binding buffer: 20 mM sodium acetate
buffer, pH 5.0. The sample, 40 ml, was applied on the columns,
which were extensively washed with 30 ml of binding buffer
afterward. Then, protein was eluted using a 15-ml gradient of
0–400 mM NaCl. Fractions containing the highest protein
activity and purity were pooled. Next, the pooled sample (4.5
ml) was applied to a HiLoadTM 16/600 SuperdexTM 200 prepa-
ration grade column (GE Healthcare). The column was first
equilibratedwith 500ml of 20mM sodium acetate buffer with 150
mM NaCl, pH 5.5, and the sample was applied to the column at a
flow rate of 1ml/min. Four samples of 2ml each, with the highest
purity and activity, were collected and concentrated using Centri-
con Plus-20, 15 ml with 10-kDamolecular cutoff (Millipore, Bed-
ford,MA)until 0.8ml.The finalmaterialwas snap-frozen in liquid
nitrogen and stored at80 °C until further use.
Protein determination
Total soluble protein content from cell lysates was measured
using the Pierce BCA protein assay kit (Thermo Fisher Scien-
tific), using BSA as a standard, according to the manufacturer’s
protocol. Pure protein concentrations weremeasured inNano-
Drop 2000c (Thermo Fisher Scientific).
Enzymatic assays and determination of kinetic parameters
Different 4-MU substrates were used to test the specificity of
A1.1. Tested substrates were the following glycosides linked to
4-MU: -D-glucopyranoside, -D-galactopyranoside, -D-ga-
lactopyranoside, -D-mannopyranoside, -L-fucopyranoside,
N-acetyl--D-galactosaminide, and N-acetyl--D-glucosamin-
ide at the following assay concentrations and pH conditions:
1.36 mg/ml, pH 5.2, 5.8, and 7; 1.25 mg/ml, pH 4.6 and 6; 0.144
mg/ml, pH 4.3; 2.7mg/ml, pH 4; 0.26mg/ml, pH 5.5; 0.4mg/ml,
pH 4.6; 1.52 mg/ml, pH 4.4, respectively. All substrates were
dissolved in 150 mM citrate/phosphate (McIlvaine) buffer, at
the appropriate pH for each enzyme, supplemented with 0.1%
(w/v) BSA. Released 4-MU was fluorometrically quantified as
described earlier (60, 61). Km and kcat values were determined
using 4-MU–-GAL substrate. Reactions were performed for
25min at 37 °C at 10 different 4-MU–-GAL concentrations in
150 mM citrate/phosphate buffer, pH 6, for A1.1 or pH 4.6 for
Fabrazyme supplemented with 0.1% (w/v) BSA. The 4-MU–-
GAL concentrations in the assays ranged from 0.074 to 4.72
mM. Protein concentrations in the assays were as follows: A1.1,
1.6 and 4 ng/ml; Fabrazyme, 2 and 5 ng/ml. GraphPad Prism7
was used for all calculations.
Activity toward lipid substrates
For activity measurement, 50 ng of A1.1 or Fabrazyme were
incubatedwith 5MNBD-C12–globotriaosylceramide, (NBD-
Gb3) for 1 h at 37 °C in 150 mM citrate/phosphate buffers at
different pHvalues (4.5–7.5), containing 0.05% (v/v) TritonX-100
and 0.2% (w/v) sodium taurocholate. The lipids were next
extracted by theBligh andDyer protocol and subjected toHPTLC
as described earlier (62). The plate was scanned for fluorescent
lipids with a Typhoon FLA 9500. Kinetics parametersKm and kcat
were determined using NBD-Gb3 substrate, at pH 4.5.
Alternatively, HPLC analysis and LC-MS/MS were used to
study hydrolysis of C18-Gb3 (Matreya, State College, PA) and
C18–lyso-Gb3 (Avanti, Alabaster, AL) by A1.1, respectively.
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For the degradation of C18-Gb3, 5 M natural lipid were incu-
bated with 3 g of pure A1.1 or Fabrazyme overnight at 37 °C.
Following extraction (Bligh and Dyer protocol), neutral glyco-
sphingolipids were analyzed by HPLC using C17-sphinganine
as internal standard (28). For lyso-Gb3, eight different concen-
trations of the lipid, ranging from 2 to 200 M, were incubated
with 2.5 g/ml of A1.1 and Fabrazyme for 45 min at 37 °C.
LC-MC/MS was used to measure glycosphingoid bases (lyso-
glycosphingolipids), as described previously (30, 49). As inter-
nal standard [13C]lyso-Gb3 was used (30). Kinetics parameters
Km and kcat were determined at pH 4.5, usingGraphPad Prism7
for calculations. The mature form of A1.1, having a mass of 39
kDa, and the mature monomer human -galactosidase (Fabra-
zyme), 51 kDa, adjusted to the carbohydratemass, were used to
calculate kcat values.
Uptake of TB474-labeled A1.1 by FD fibroblasts and confocal
microscopy
Fabry fibroblasts from two different patients were grown in
12-well plates. Different amounts of pre-labeled TB747 with
A1.1 were added to 500 l of the culture media. The amounts
were 0, 2.5, 5, 35, 75, and 150 g. After overnight incubation,
the cells were extensively washed with PBS and lysed in 100 l
of ice-cold 50mMphosphate buffer, pH 6.5, supplementedwith
0.1% Triton X-100. The total protein content of the cells was
measured. Then 10g of total protein of the lysates, accounting
to 15–20% of total cell lysate, were analyzed in SDS-PAGE.
Quantification of the gels took place using ImageJ program.
The pre-labeling of the enzyme was done for 4 h, at room tem-
perature, in 150 mM citrate/phosphate buffer, pH 5.5, at a final
TB474 concentration of 0.25 M, 100-l volume, followed by
removal of unbound TB474 by passing the sample over a 0.7-ml
PierceTM polyacrylamide spin desalting column 7000 MWCO
(Thermo Fisher Scientific), according to the manufacturer’s
protocol.
For the confocal microscopy experiments, the same Fabry
fibroblasts were grown in 12-well plates containing coverslips,
until they reached 70–80% confluency. On the day of the
uptake, the culture medium was removed, and 500 l of fresh
culture medium was placed in each well. 75 g of A1.1 pre-
labeled with TB474 was applied to the fibroblasts overnight.
After the incubation, the fibroblasts were washed extensively
with PBS and subsequently were fixed with 4% (w/v) formalde-
hyde/PBS for 25 min at room temperature. After the fixation,
the cells were washed three times quickly with PBS and incu-
bated for 10 min with 2% (w/v) BSA and 0.1% (w/v) saponin in
PBS (“permeabilization buffer”). To stain for LAMP-1, the cells
were incubated for 1 h at room temperature with rabbit anti-
LAMP-1 antibody (Abcam) at a dilution of 1:400 in permeabi-
lization buffer. The cells were washed three times in permeabi-
lization buffer and incubated for 1 h at room temperature with
Alexa Fluor 488-coupled donkey anti-rabbit IgG (Invitrogen),
1:500 in permeabilization buffer. After the incubation, the cells
were further washed in permeabilization buffer and quickly
with distilled water. The coverslips were mounted on a micro-
scope slide (VWR) with ProLong Diamond antifade reagent
containing DAPI (Molecular Probes). Imaging of the cells was
performedwith aLeica SP8 confocalmicroscopewith a63/1.40
NA HC Plan Apo CS2 oil immersion objective and equipped
with a hybrid detector. TB474-labeled A1.1 was imaged with
excitation at 638 nm and emission at 650–700 nm; LAMP-1
with excitation at 488 nm and emission at 500–540 nm; and
DAPI at 405 nm excitation and emission at 420–480 nm.
A1.1 treatment of FD fibroblasts
FD fibroblasts were grown in 12-well plates in a humidified
incubator at 37 °Cwith 5%CO2. To 500l of the culturemedium,
150g ofA1.1 were added, followed by overnight incubation.
Next, cells were extensively washed in PBS, collected, and
lysed in 100 l of ice-cold 50 mM phosphate buffer, pH 6.5,
supplemented with 0.1% Triton X-100. Protein determina-
tion of lysates took place, and the lysates were used for lipid
extractions, following LC-MS/MS analysis and 4MU–-
GAL activity assays.
Crystallization conditions and data collection
Purified A1.1 was concentrated to 5 mg/ml and incubated
with 10 M TB474 for 30 min at room temperature. After
incubation, crystallization conditions were screened by sitting-
drop vapor diffusion using the JCSG kit Premier (Molecular
Dimensions). The screeningswere performed by theNT8 robot
(Formulatrix) at 20 °C, using 200 nl drops, with awell volume of
70l. After 12 h the crystals were formed at theH9 condition of
the JCSG screening. The condition consisted of 0.1 M BisTris
buffer, pH 5.5, 0.2 M LiSO4, 25% w/v PEG 3350. The crystal had
a rhombus shape with 30.7/37-m size. The crystal was flash-
frozen in liquid nitrogen using 20% glycerol as a cryo-protectant.
X-ray data collection was performed at the ESRF (Grenoble,
France) on beamline ID30A-3, using a PIXEL, Eiger_4M
(DECTRIS), X-ray detector. A total of 1900 images were col-
lected, with an oscillation of 0.05° and exposure time of 0.01 s
(total of 19 s). Then the data were processed by XDS and scaled
by AIMLESS. The structure was solved using the molecular
replacement method (MOLREP), having 1UAS as search model,
through theCCP4 suite and further refinedusingREFMAC.Man-
ualmodelbuildingwasdoneusingCoot. Imagesof structureswere
obtained using CCP4mg, and amino acid alignments were per-
formed using ClustalOmega and ESPript3.0.
The superposition of A1.1 and human proteins was per-
formed by secondary structure-matching (59), using the A
monomer of human -galactosidase (PDB 3HG2) and our
structure. Secondary structure matching aligned 348 residues
with a root-mean-square deviation of 1.3358 Å of the C-
atoms of the aligned residues.
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